(Q35546416)

8 August 2017

title

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates (English)

1 reference

8 August 2017

1 reference

1 reference

Iqbal S Grewal

1 reference

8 August 2017

Sean K Kelley

1 reference

8 August 2017

Thomas Gelzleichter

1 reference

8 August 2017

Dong Xie

1 reference

8 August 2017

Wyne P Lee

1 reference

8 August 2017

Walter C Darbonne

1 reference

8 August 2017

Ferhan Qureshi

1 reference

8 August 2017

Kim Kissler

1 reference

8 August 2017

Ezogelin Oflazoglu

1 reference

8 August 2017

language of work or name

English

0 references

publication date

10 July 2006

1 reference

British Journal of Pharmacology

8 August 2017

published in

1 reference

8 August 2017

volume

148

1 reference

8 August 2017

1 reference

8 August 2017

page(s)

1116-1123

1 reference

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

The role of the CD40 pathway in the pathogenesis and treatment of cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

A stimulating new target for cancer immunotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

The CD40 antigen and its ligand

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Interspecies scaling and comparisons in drug development and toxicokinetics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Signalling pathways of the TNF superfamily: a double-edged sword

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Prospects for CD40-directed experimental therapy of human cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40 activation as potential tool in malignant neoplasms.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

CD40 ligand induces an antileukemia immune response in vivo.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

A novel function of CD40: induction of cell death in transformed cells

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752010

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

26 September 2018

1 reference

12 December 2020

Inhibition of human B-cell lymphoma growth by CD40 stimulation

1 reference

12 December 2020

Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells

1 reference

12 December 2020

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies

1 reference

12 December 2020

CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis

1 reference

12 December 2020

CD40 and epithelial cells: across the great divide

1 reference

12 December 2020

Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand

1 reference

12 December 2020

Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14

1 reference

12 December 2020

Phase I study of recombinant human CD40 ligand in cancer patients

1 reference

12 December 2020

Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJP.0706828

1 reference

8 August 2017

1 reference

8 August 2017

1 reference